BiomX Inc. reported its financial results for the first quarter ended March 31, 2025, on May 15, 2025. The company's cash balance and restricted cash were $21.2 million as of March 31, 2025, an increase from $18.0 million at December 31, 2024, primarily due to funds raised in the February 2025 financings.
Net loss for Q1 2025 was $7.7 million, a decrease from $17.3 million in Q1 2024, mainly attributed to the change in the fair value of warrants issued in the March 2024 financing. Research and development expenses, net, increased to $5.3 million from $4.1 million, driven by preparations for the BX004 Phase 2b trial and increased expenses for the BX211 Phase 2 trial.
Shareholders approved the exercise of certain warrants issued as part of the company’s $12 million financings announced in February 2025, during a Special Meeting on April 21, 2025. These financings are expected to provide a cash runway to support activities into the first quarter of 2026, aligning with the anticipated readout of topline Phase 2b results for BX004.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.